Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurimmune AG

www.neurimmune.com

Latest From Neurimmune AG

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

On The Path To Regeneration: NovaGo’s New Approach To Stroke

Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.

Regenerative Medicine StartUps and SMEs

Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases

Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.

Financing Business Strategies

AbbVie Validates Voyager’s One-Shot Approach With Parkinson’s Collaboration

AbbVie and existing partner Voyager Therapeutics are attempting to cross the blood-brain barrier with a new collaboration on vectorized antibodies to treat Parkinson’s disease and other synucleinopathies such as Lewy body dementia and multiple system atrophy.

 

Neurology Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neurimmune Therapeutics AG
  • Neurimmune Holdings AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Neurimmune AG
  • Senior Management
  • Roger Nitsch, Pres. & CEO
    Dirk Schimkat, CFO
    Jan Grimm, PhD, CSO
    Fabian Buller, CBO
    Christoph Hock, MD, CMO
    Michael Salzmann, PhD, COO
  • Contact Info
  • Neurimmune AG
    Phone: (41) 44 755 4646
    Wagistrasse 13
    Schlieren-Zurich, CH-8952
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register